Proactive Investors - Run By Investors For Investors

Medlab Clinical expanding cannabis-based medicines into Europe

By having a European subsidiary, Medlab can save on drug registration fees.
Euro sign
In Australia, Medlab has proceeded to stage II for its cannabis cancer trial

Medlab Clinical Ltd (ASX:MDC) has formally incorporated a wholly owned subsidiary MDC Europe Limited to facilitate expansion into Europe.

The subsidiary will be used specifically for current and future dealings regarding NanaBis™ and the proposed drug registration models as per the European Medicines Agency (EMA). 

NanaBis™ is one of two of Medlab’s cannabis-based medicines which contains formulations of tetrahydrocannabinol (THC) and cannabidiol (CBD).

European registration of NanaBis™ progressing

Meetings have been held with EMA on the pathway for registration of NanaBis™.

Conditional approval is likely. Registration with a significant fee reduction requires the company to be domiciled in Europe.

Medlab’s CEO Dr Sean Hall said: “MDC as a Group is strategically placed to progress commerce in Europe through potential trade deals, especially in conjunction with the recently announced granting of an export licence for NanaBis™.

“This move is also very exciting as it provides NanaBis™ an introduction into Europe as a potentially future compliant drug.” 

READ: Medlab Clinical proceeding to stage II for cannabis cancer trial

In late October 2018, Medlab successfully completed stage I of the NanaBis™ human trial on cancer patients at Royal North Shore Hospital.

The trial is progressing as planned and currently in stage II of the Ethics approved trial.

This NanaBis™ program will serve as an integral part of both domestic and foreign regulatory approvals.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full MDC profile View Profile

Medlab Clinical Ltd Timeline

Related Articles

cannabis
August 28 2018
Tidal Royalty provides capital to help grow licenced US cannabis firms in exchange for receiving a percentage of future top-line revenues.
Laboratory testing
October 09 2018
Fifteen patients have been enrolled in the trial being carried out at Children’s Hospital of Philadelphia in the USA.
muffins and cannabis
November 29 2018
Dehydratech is essentially a delivery system that allows drugs and vitamins to get into the bloodstream quicker, while making them taste and smell better at the same time

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use